Related Experiment Videos
L-carnitine adjuvant therapy in essential hypertension
1Florence University Medical School, Third Institute of Clinical Medicine and Medical Therapy.
La Clinica Terapeutica
|May 1, 1994
Summary
L-carnitine supplementation improved essential hypertension symptoms, reducing asthenia and decreasing triglyceride levels in patients also taking antihypertensive drugs.
Area of Science:
- Cardiology
- Metabolic Disorders
Background:
- Essential hypertension is a prevalent cardiovascular condition.
- Asthenia and lipid abnormalities are common comorbidities.
Purpose of the Study:
- To evaluate the therapeutic effects of L-carnitine in patients with essential hypertension.
- To assess L-carnitine's impact on asthenia, electrocardiographic parameters, and lipid profiles.
Main Methods:
- A randomized controlled study involving patients with essential hypertension.
- Group A1 received antihypertensive drugs plus L-carnitine; Group A2 received antihypertensive drugs only.
- Group B received L-carnitine monotherapy.
- Evaluations included ECG, asthenia assessment, and biochemical markers (lipids, electrolytes, creatinine, glucose).
Main Results:
- Subgroup A1 showed improvement in asthenia and reduction in extrasystoles and ventricular repolarization changes.
- Significant decrease in serum triglyceride levels observed in subgroup A1 (148 to 121 mg/dl, p < 0.025).
- L-carnitine monotherapy (Group B) also showed positive effects, though not detailed in the truncated abstract.
Conclusions:
- L-carnitine demonstrates therapeutic potential as an adjunct treatment for essential hypertension.
- L-carnitine may help manage associated symptoms like asthenia and improve lipid profiles, specifically triglycerides.